Terazosin

ArtNr	HY-B0371-10mM
Hersteller	MedChem Express
CAS-Nr.	63590-64-7
Menge	10 mM
Kategorie	Oncology Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer
Typ	Inhibitors
Specific against	other
Purity	985.000
Citations	[1]Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.\|[2]Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.\|[3]Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851. Authorea. March 31, 2022. Eur J Med Chem. 2024 Mar 5:267:116209. Neurochem Int. 2021 Feb:143:104942. Research Square Preprint. 2022 Jul. Cell Prolif. 2025 Mar;58(3):e13764. Cell Rep Methods. 2023 Oct 23;3(10):100599. Res Sq. 2025 Mar 16.
Smiles	O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - HS Code	H302-H315-H319-H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Product Description	Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
Manufacturer - Research Area	Metabolic Disease; Endocrinology; Cardiovascular Disease
Solubility	DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Clinical information	Launched
Isoform	α adrenergic receptor
UNSPSC Code	12352005
Precautionary	P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.